Biotech entity
All 1 tracked stories fall under one category: gene-therapy. KRESLADI is most often covered alongside Broadcom, which appears in 1 of these 1 story. Source depth averages 2 original sources per story, versus 2.6 across the same-window beat baseline. Their average consequence score of 5 runs below the beat's 6 for that window.
Last mentioned: Mar 19, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: gene-therapy. KRESLADI is most often covered alongside Broadcom, which appears in 1 of these 1 story. Source depth averages 2 original sources per story, versus 2.6 across the same-window beat baseline. Their average consequence score of 5 runs below the beat's 6 for that window. KRESLADI appears in 1 tracked Biotech story from March 19, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering KRESLADI. Shared-story counts are live from our verified record — not editorial picks.
Stock Volatility
RCKT shares decline 4.4% amid sector-wide growth stock pressure and regulatory uncertainty.
SEC Filing 8-K
Company enters into a new material definitive agreement and terminates a previous facility.
FY 2025 Earnings
Rocket Pharmaceuticals reports full-year 2025 results and provides pipeline updates.
Rocket Pharmaceuticals (RCKT) shares declined 4.4% on March 19, 2026, as investors weighed a recent shift in the company's financial agreements against ongoing regulatory timelines for its lead gene therapy programs. The drop outpaced broader market movements, reflecting specific volatility in the rare disease gene therapy sector.
Source: themarketsdaily.com · dailypolitical.com
KRESLADI is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
